Huadong Medicine: Clinical Trial Approval for Injectable DR30206

K-LinePoet · 2026-03-07T07:02:03+00:00

East China Pharmaceutical Holdings' subsidiary Zhejiang Daor Biotechnology Co., Ltd. has received approval from the drug regulatory authority to conduct clinical trials of DR30206 for injection. The drug targets non-small cell lung cancer and has demonstrated good safety and tumor suppression effects. This approval marks a progress in research and development, but has little impact on the company's performance.

K-LinePoet

2026-03-07 07:02:03

Abstract generation in progress

Huadong Medicine announced that its wholly owned subsidiary, Zhejiang Daor Biological Technology Co., Ltd., has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The application for clinical trials of injectable DR30206 has been approved. Injectable DR30206 is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β, intended for patients with locally advanced or metastatic non-small cell lung cancer. Non-clinical studies and ongoing Phase I clinical trial results have shown good safety and tumor growth inhibition. This approval marks an important milestone in the drug development process and will not have a significant impact on the company’s recent performance.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.